Published in Glob J Biochem on March 08, 2011
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 21.42
Cancer cell cycles. Science (1996) 21.29
A 5-decade analysis of 13,715 carcinoid tumors. Cancer (2003) 12.78
NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature (1999) 10.48
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Phosphoinositide kinases. Annu Rev Biochem (1998) 8.51
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
An analysis of 8305 cases of carcinoid tumors. Cancer (1997) 6.24
PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci (1997) 3.68
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med (1999) 2.92
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol (1997) 2.46
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res (2006) 2.21
Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis (2005) 2.02
Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res (1997) 1.92
Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg (1999) 1.92
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res (2000) 1.90
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer (2008) 1.88
Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg (1998) 1.83
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2003) 1.76
Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors. J Cell Biol (2003) 1.67
Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res (2001) 1.63
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem (2005) 1.59
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A (2010) 1.45
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery (2003) 1.37
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res (1998) 1.37
Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem (2004) 1.37
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery (2006) 1.34
Treatment of advanced carcinoid tumors. Curr Opin Oncol (2006) 1.32
Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery (2005) 1.28
VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer (2011) 1.27
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther (2002) 1.20
Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg (2004) 1.18
The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs (2006) 1.17
The malignant carcinoid syndrome. Surg Gynecol Obstet (1973) 1.15
Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol (2002) 1.15
In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene (2002) 1.13
Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am J Surg (2008) 1.13
Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol (2006) 1.09
Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene (1995) 1.08
Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J (2002) 1.06
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer (2010) 1.06
Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev (2007) 1.05
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol (1999) 1.00
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg (2009) 1.00
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol (2000) 0.95
Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther (2000) 0.94
AKT and PTEN expression in human gastrointestinal carcinoid tumors. Am J Transl Res (2009) 0.94
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J (2000) 0.94
Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Ann Surg Oncol (2009) 0.93
Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene (2005) 0.90
The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer. Surgery (2008) 0.84
The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol (2001) 0.81